The Lancet Regional Health - Europe · 2023 · 42 citations · 26 references
PharmacyCardiologyPharmacotherapyCardiovascular PharmacotherapyClinical CardiologyClinical Decision SupportCardiovascular DiseaseCardiovascular RiskCardiovascular Risk ReductionDyslipidemia ManagementLipid ManagementLipid-lowering TherapyLow-density Lipoprotein Cholesterol LoweringLow-density Lipoprotein Cholesterol ReductionPcsk9 Inhibitor TherapyPcsk9 InhibitorsProprotein Convertase Subtilisin/kexin Type 9 InhibitionProprotein ConvertasesTreatment Algorithm DevelopmentTreatment Optimisation
The impact of the stepwise implementation of the 2019 European Society of Cardiology (ESC)/European Atherosclerosis Society (EAS) treatment algorithm on low-density lipoprotein cholesterol (LDL-C) goal attainment was simulated in patients from the DA VINCI study. Monte Carlo simulation was used to evaluate treatment optimisation scenarios, based on a patient's risk category: statin intensification (step 1), addition of ezetimibe (step 2), and addition of a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor (step 3). Residual cardiovascular risk and predicted relative and absolute risk reduction (RRR and ARR) in cardiovascular events were assessed. In DA VINCI, 2482 patients did not achieve their 2019 ESC/EAS LDL-C goals and were included in the simulation. In patients without atherosclerotic cardiovascular disease (ASCVD) (n = 962), 27.0% (n = 259) and 57.0% (n = 548) are likely to achieve their LDL-C goals at step 1 and step 2, respectively. Of those at very high risk without ASCVD (n = 74), 88.1% (n = 65) are likely to achieve their LDL-C goals at step 3. In patients with ASCVD (n = 1520), 12.0% (n = 183), 42.1% (n = 641) and 93.2% (n = 1416) are likely to achieve their LDL-C goals at steps 1, 2 and 3, respectively. In patients with and without ASCVD, treatment optimisation may result in mean simulated RRR of 24.0% and 17.7%, respectively, and ARR of 8.1% and 2.6%, respectively. Most patients at high cardiovascular risk are unlikely to achieve LDL-C goals through statin optimisation and ezetimibe, and will require a PCSK9 inhibitor, leading to greater reduction in cardiovascular risk. Amgen.
26
2018 ESC/ESH Guidelines for the management of arterial hypertension
Bryan Williams, Giuseppe Mancia, Wilko Spiering et al. · European Heart Journal · 2018 · 10.4K citations · Full text
Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia
Frederick J. Raal, David Kallend, Kausik K. Ray et al. · New England Journal of Medicine · 2020 · 801 citations · Full text
Kausik K. Ray, Bart Molemans, W. Marieke Schoonen et al. · European Journal of Preventive Cardiology · 2020 · 767 citations · Full text